Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 03, 2015 7:43 AM ET

Company Overview of Multiple Myeloma Research Consortium

Company Overview

51 Locust Ave Ste 201

New Canaan, CT 06840-4739

United States

Founded in 1996

Phone:

203-972-1250

Key Executives for Multiple Myeloma Research Consortium

Founder and Chief Executive Officer
Age: 56
Compensation as of Fiscal Year 2015.

Multiple Myeloma Research Consortium Key Developments

Multiple Myeloma Research Consortium Opens Six New Clinical Trials in 2014

Multiple Myeloma Research Consortium announced that it has opened six new clinical trials in 2014, and is on track to open more multiple myeloma clinical trials during 2014 than any other year. Phase I, Multicenter, Open-Label, Dose-Escalation Combination study of Marizomib, Pomalidomide, and Low-Dose Dexamethasone (PMD) in subjects with relapsed or refractory multiple myeloma. Marizomib is a novel proteasome inhibitor from Triphase -- in the same class as Velcade (bortezomib) and Kyprolis (carfilzomib) -- that has been studied in Phase I single agent trial in the MMRC. Investigators believe that it can work in patients who are resistant to other proteasome inhibitors. Multicenter, Phase I/IIb Study of Ibrutinib, in combination with Kyprolis in subjects with relapsed or relapsed and refractory multiple myeloma. Ibrutinib blocks a protein called Bruton's tyrosine kinase (Btk), and is an oral drug already approved by FDA for Chronic Lymphocytic Leukemia. Phase I Study of the combination of a Selective Inhibitor of Nuclear export (SINE), Selinexor (KPT-330), with Kyprolis and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Phase I Study of SAR650984 for the treatment of relapsed or refractory multiple myeloma (NCT1084252). SAR650984 is an anti-CD 38 monoclonal antibody therapy that is being studied in combination with lenalidomide and dexamethasone in the MMRC. Early results suggest that this combination treatment may be effective in patients who have failed other options. A Phase I/II trial of Ixazomib (MLN9708) in combination with Pomalyst (pomalidomide) and dexamethasone for relapsed or relapsed refractory multiple myeloma. MLN9708 is the first oral proteasome inhibitor and provides a much easier and more convenient route of drug administration. Phase I, Open Label, Dose-Escalation study of first in man study of CB-5083, the first p97 inhibitor to enter clinical trials. Several MMRC member institutions worked closely with manufacturer Cleave Biosciences on the preclinical work, which suggested activity in multiple myeloma. CB-5083 targets a novel protein that is involved in protein degradation and the proteasome pathway and inhibits this pathway at a different intervention point than the proteasome inhibitors, Velcade and Kyprolis.

Similar Private Companies By Industry

Company Name Region
Jaeger Construction Inc. United States
Roscoe Community Bankshares, Inc. United States
Universal Medical Concepts, Inc. United States
TriLogic Corporation United States
County Title Holding Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Multiple Myeloma Research Consortium, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.